Journal
JOURNAL OF PINEAL RESEARCH
Volume 67, Issue 2, Pages -Publisher
WILEY
DOI: 10.1111/jpi.12587
Keywords
apoptosis; HDAC9; melatonin; NSCLC; prognosis; proliferation
Categories
Funding
- National Natural Science Foundation of China [81572252, 81871866] Funding Source: Medline
- Natural Science Foundation of Shaanxi Province [2019SF-033, 2016SF-308] Funding Source: Medline
- Excellent Doctoral Support Project of the Fourth Military Medical University [2018D09] Funding Source: Medline
- Project of Tangdu Hospital, The Fourth Military Medical University [2018 Key Talents, 2015 Key Talents] Funding Source: Medline
Ask authors/readers for more resources
Histone deacetylase 9 functions as an oncogene in a variety of cancers, but its role on non-small cell lung cancer (NSCLC) has not been reported. Melatonin was proven to possess anticancer actions, whereas its effect on NSCLC and underlying mechanisms remains poorly understood. In this study, 337 patients with complete clinicopathologic characteristics who underwent NSCLC surgery were recruited for the study. We found that NSCLC patients with high HDAC9 expression were correlated with worse overall survival and poor prognosis. HDAC9 knockdown significantly reduced NSCLC cell growth and induced apoptosis both in vivo and in vitro. Melatonin application also markedly inhibited cell proliferation, metastasis, and invasion and promoted apoptosis in NSCLC cells. Moreover, RNA-seq, real-time quantitative polymerase chain reaction, and western blot analyses showed that melatonin treatment decreased the HDAC9 level in NSCLC cells. A mechanistic study revealed that HDAC9 knockdown further enhanced the anticancer activities of melatonin treatment, whereas HDAC9 overexpression partially reversed the melatonin's anticancer effects. Additionally, the in vivo study found melatonin exerted anti-proliferative and pro-apoptotic effects on xenograft tumors which were also strengthened by HDAC9 knockdown. These results indicated that HDAC9 downregulation mediated the anti-NSCLC actions of melatonin, and targeting HDAC9 may be the novel therapeutic strategy for NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available